| Identification | Back Directory | [Name]
Ataciguat | [CAS]
254877-67-3 | [Synonyms]
HMR 1766
Ataciguat
Ataciguat
(HMR-1766
5-Chloro-2-[[(5-chloro-2-thienyl)sulfonyl]amino]-N-[4-(4-morpholinylsulfonyl)phenyl]benzamide
Benzamide, 5-chloro-2-[[(5-chloro-2-thienyl)sulfonyl]amino]-N-[4-(4-morpholinylsulfonyl)phenyl]- | [Molecular Formula]
C21H19Cl2N3O6S3 | [MDL Number]
MFCD09837865 | [MOL File]
254877-67-3.mol | [Molecular Weight]
576.49 |
| Chemical Properties | Back Directory | [density ]
1.613±0.06 g/cm3(Predicted) | [solubility ]
DMF: 1 mg/ml; DMF:PBS(pH 7.2)(1:1): 0.5 mg/ml | [form ]
A crystalline solid | [pka]
5.70±0.50(Predicted) | [color ]
White to off-white | [InChIKey]
PQHLRGARXNPFCF-UHFFFAOYSA-N | [SMILES]
C(NC1=CC=C(S(N2CCOCC2)(=O)=O)C=C1)(=O)C1=CC(Cl)=CC=C1NS(C1SC(Cl)=CC=1)(=O)=O |
| Hazard Information | Back Directory | [Uses]
Ataciguat, formerly referred to as HMR-1766, a novel anthranilic acid derivative, belongs to a new structural class of sGC activators capable of activating the oxidized form of sGC. Ataciguat has been shown to improve endothelial function and to reduce platelet activation in exptl. diabetes. Chronic regular treatment with sGC activators such as ataciguat could therefore eventually constitute an effective therapy targeting deficient NO/cGMP signaling in hypertension, peripheral and coronary artery disease, heart failure, thrombosis and erectile dysfunction. |
|
| Company Name: |
J & K SCIENTIFIC LTD.
|
| Telephone: |
18210857532 18210857532 |
| Website: |
https://www.jkchemical.com |
| Company Name: |
SPIRO PHARMA
|
| Telephone: |
|
| Website: |
www.spiropharma.com.cn |
|